Long Term Follow-Up for RGX-111
← catalyst calendarNCT06103487 · readout ≤ 406 d
Sponsored by REGENXBIO Inc. (industry) · RGNX — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
21estimated
Sites
2
Countries
Brazil, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-24 | actual | When the study began enrolling |
| Primary completion | Sep 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mucopolysaccharidosis I
Intervention
- Genetic: No Intervention
Primary outcome
what the primary-completion date above is the date OFEvaluation of the long-term safety of RGX-111
measured 5 years inclusive of parent study
Permalink · RGNX's whole pipeline · Catalyst calendar · Every registered study · What changed